H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on electroCore (ECOR) to $25 from $22 and keeps a Buy rating on the shares after the company entered into a definitive merger agreement to acquire NeuroMetrix. The acquisition appears to be to the benefit of electroCore, without expected material dilution of the company’s cash or equity, the analyst tells investors in a research note. The firm says Quell expands its non-invasive pain therapy portfolio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECOR: